Natco Pharma Gains FDA Tentative Approval for New Oncology Drug

Natco Pharma Ltd, a well-known mid-cap pharmaceutical company listed on the NSE, announced yesterday that it has received tentative approval from the U.S. Food and Drug Administration for its generic version of Erdafitinib tablets, a treatment used in advanced urothelial carcinoma, a type of bladder cancer. This regulatory milestone marks a strategic expansion in Natco’s oncology portfolio and positions the company to capture significant sales opportunities in the U.S. market, where the reference drug reportedly generated around $60 million in annual sales. The tentative FDA approval for multiple dosage strengths was disclosed through a regulatory filing under SEBI rules and could boost investor sentiment around the stock given its potential revenue uplift. In today’s trade, Natco Pharma’s share price reflected mixed sentiment, moving in a range but showing resilience amid broader market volatility on the NSE. Analysts note that entering this high-growth segment could strengthen the firm’s long-term earnings profile. This development adds to a series of regulatory and growth catalysts for the company as it aims to expand both domestic and international footprints. Investors will be watching how the final FDA approval and subsequent market uptake unfold in coming sessions. Disclaimer: Investments in securities are subject to market risk. This is for educational purposes only. Investors must verify information before investing and consider their financial position & risk profile.